Anvisa, the health regulator of Brazil, has extended the validity of the single-shot US pharmaceutical company Johnson & Johnson (J&J) (NYSE:JNJ) COVID-19 vaccine, prolonging its shelf life from three months to 4.5 months, Reuters news agency reported on Tuesday.
This gives Brazil more time to use a first batch due to arrive this week.
Reportedly, the batch of three million doses was due to expire on 27 June 2021, but now Brazil has followed the US Food and Drug Administration in extending the expiration dates by a month a half.
Brazil's Health Minister said the vaccines should arrive on Wednesday, a day later than stated last week.
Reportedly, Brazil had signed an agreement with the J&J-owned Belgian laboratory Janssen to receive 38 million doses for delivery in the last quarter of this year.
This first batch of vaccine doses is arriving earlier than originally planned.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval